Fig. 6. Non-activated CAR T cells generated from patient samples show potent efficacy in vivo.
a–d, Serial quantification of disease burden by bioluminescence imaging. Total BLI in mice treated with 3 × 106 non-activated T cells (d1) transduced as in Fig. 4e (a; n = 7), CAR T cells stimulated with anti-CD3/CD28 microbeads and expanded over 9 d (d9; b; n = 10) or NTD control non-activated T cells (c; n = 10) as well as the total BLI of untreated mice (tumour only; d). In a and b, the dashed line is the baseline BLI. e, BLI measurement of the disease burden of the mice from the d1 and d9 groups (from a and b) in relation to the absolute CD45+ T-cell counts in their peripheral blood on d49. f–h, Absolute CD45+ T-cell counts, measured using a TruCount assay, of peripheral blood collected from the mice in a–c on d16 (f), d23 (g) and d49 (h) following the T-cell transfer. The mean of each group is indicated by the solid black line. Groups were compared using a two-tailed unpaired Mann–Whitney test. ***P = 0.0001; **P = 0.002.